Fredericamycin A (FMA) is an antibiotic product of Streptomyces griseus that exhibits modest antitumor activity in vivo and in vitro, but, its functions in vivo are poorly understood. We identified this compound as an inducer of G1 arrest in the yeast, Saccharomyces cerevisiae. FMA exhibits an IC50 of 24 nM towards the growth of a disruptant of multi-drug resistance genes, W303-MLC30, and its cytotoxicity is a function of the time of exposure as well as drug dose. Addition of 0.8 M of FMA caused aggregation of mitochondria within 10 min of incubation and the drug induced petites at high frequency after 4 h of incubation. rho À cells were about 20 times more resistant to FMA than isogenic rho þ cells. Overexpression of topoisomerase I, a previously suggested target of the drug, did not alleviate the sensitivity of the cells to FMA or the aggregation of mitochondria. Our results suggest that mitochondria are the primary target site of FMA.
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Key words: fredericamycin A; mitochondria; Saccharomyces cerevisiae; petite; G1 arrest Fredericamycin A (FMA), a product of Streptomyces griseus, exhibits antibacterial, antifungal, and antitumor activity and has no DNA binding activity. 1) Earlier studies suggest that it can act by spontaneously forming on oxidized free radical, with subsequent electron transfer to molecular oxygen, 2) but, biological evidence supporting this hypothesis has not been shown. Lathman et al. reported that FMA inhibits in vitro activity of topoisomerases I and II and DNA polymerase , 3) however, the mechanism of action of the drug in vivo is obscure.
We identified FMA as a cell-cycle modulator of the budding yeast Saccharomyces cerevisiae. In this study, we examined the effect of FMA on yeast cells and found that the drug shows potent activity to induce mutations defective of respiration (petites) and morphological change in mitochondria. Mitochondria are essential organelles that perform a large number of reactions in eukaryotic cells in addition to creating the vast majority of the ATP necessary to support all cellular functions. Resent studies show that mitochondria have a key role in apoptosis and aging, and mitochondrial genetic defects have been found to be involved in the pathogenesis of a number of human diseases including cancer. [4] [5] [6] Our results suggest that the target(s) of FMA might be a protein(s) involved in the maintenance of mitochondrial morphology, and their inheritance.
Materials and Methods
Strains, media and plasmids. S. cerevisiae strains used were W303-1A (MATa ura3-1 leu2-3,112 trp1-1 his3-11 ade2-1 can1-100) and W303-MLC30 (W303 background yrs1Á::HIS3 yrr1Á::TRP1 pdr1Á::hisG-URS3-hisG pdr3Á::hisG-URS3-hisG). 7) Cells were grown at 28 C in liquid YPD (1% yeast extract, 2% peptone, 2% glucose). YPGly contains 3% glycerol instead of glucose in YPD. Diydrorhodamine 123 was obtained from Sigma (Boston, MA).
YCpGFP-COX4 and YEpTOP1 were gifts of Shuhichi Nishikawa and Akihiko Kikuchi respectively. Standard genetic methods were used. 8) Flow cytometry. Overnight culture of yeast in YPD y To whom correspondence should addressed. Tel/Fax: +81-82-424-7868; E-mail: etsuchi@hiroshima-u.ac.jp Abbreviations: DMSO, dimethylsulfoxide; FMA, fredericamycin A; IC50, half-inhibitory concentration; mtDNA, mitochondrial DNA; PI, propidium iodide; ROS, reactive oxygen species medium was diluted to 5 Â 10 5 /ml and allowed to grow to 1:5 $ 2 Â 10 6 /ml before the addition of FMA. Approximately 1 Â 10 7 cells were withdrawn from these cultures and processed for propidium iodide staining. 9) For each preparation, 20,000 events were analyzed for DNA content using an Epics Elite (Beckman Coulter) flow cytometer.
Southern blot analysis. DNA preparation and Southern blots were carried out according to standard methods. 8) A mitochondrial DNA probe was prepared by labeling the EcoRI digest of isolated mitochondrial DNA (a gift of Shu-ichi Nishikawa) with digoxigenin using a DIG-labeling kit (Roche).
Results and Discussion
Identification of fredericamycin A as a cell cycle modulator of S. cerevisiae In order to identify novel cell-cycle inhibitors, we screened for activity that arrests yeast cell growth at the unbudded G1 stage, on culture supernatant of several thousand strains of actinomycestes. Among those, broth of strain No. SNA-16323 showed potent activity. The active compound was purified from a culture broth of this strain by ethyl acetate extraction under acidic conditions, by silica gel column chromatography (CHCl 3 :CH 3 OH = 50:1 to 10:1) and HPLC (50% CH 3 CN). IR, MS 1 H NMR and 13 C NMR spectra indicated that it was identical to fredericamycin A 10) (FMA, Fig. 1A and data not shown). The purified drug was dissolved in dimethylsulfoxide (DMSO) at 2 mg/ml and used for the experiments. We used only the basic (blue) form of the drug.
The half-inhibitory concentration (IC50) of FMA on the growth of W303-MLC30, estimated by fold increase of cell numbers during 10 h incubation, was 0.013 mg/ml (24 nM), and over 90% inhibition was observed at 0.1 mg/ml (Fig. 1B, rho þ ). W303-MLC30 is a strain carrying deletion of multi-drug resistance genes, and it showed 10 times higher sensitivity to the drug than its parental strain, W303-1A. To assess the effect of FMA on cell-cycle progression, we examined the DNA content of the cells by fluorescence-activated cellsorting (FACS) analysis. In the presence of 0.5 mg/ml (0.9 mM) of FMA, accumulation of the cells with 1C DNA content was observed after 4 h of incubation, but little change in the cells with 1C DNA in the culture added with drug vehicle, DMSO (0.025%, Fig. 1D ). The morphology of the cells and nuclei stained with propidium iodide (PI) showed that over 68% of the cells treated with 0.5 mg/ml of FMA for 6 h have no bud and a single nucleus, which suggests that the drug induces an accumulation of G1-cells.
FMA induces petites at high frequency
Although FMA caused an accumulation of G1 cells, the effect of the drug was not fully reversible. After 4 h of treatment with FMA, the viability of the cells, assessed by colony forming assay, decreased to 10% of control DMSO treated cells ( Fig. 2A, closed and open circles). In the course of this experiment, we noticed that the growth of the colonies of FMA-treated cells was notably slower than that of the DMSO treated cells (data not shown). This result suggests the possibility that FMA affects mitochondria to induce respiration defects. To assess this possibility, we tested the colony-forming ability of FMA treated cells on plates containing nonfermentable carbon source glycerol (YPGly). FMA treatment strongly reduced colony formation of the cells on YPGly plate. The colony-forming ratio of the cells on the YPGly plate after 4 h and 8 h of treatment with FMA was 0.04% and 0.009% of that of the DMSO treated cells (Fig. 2A, closed and open squares) respectively, about 250 and 780 times lower than that on the YPD plate at the respective times, 10% and 7%. This growth pattern, referred as a petite phenotype, 11) is characteristic of strains with defective mitochondrial respiration and indicates that FMA disrupts normal mitochondrial function.
Petite mutation is frequently associated with large deletion or complete loss of mitochondrial DNA (mtDNA). The mutations are called rho À or rho 0 respectively, 11) and enhanced degradation of mtDNA by drugs such as ethidium bromide or a mutation in the genes involved in mtDNA replication often induces the rho À /rho 0 mutation. 12) Because cell numbers increased to about four times that of the initial value by 6 h incubation in the presence of 0.5 mg/ml of FMA (Fig. 1C) , degradation of mtDNA was expected to be detectable by Southern blot analysis with total mtDNA as a probe. To examine this issue, total DNA was prepared from FMA-or DMSO-treated cells, digested with EcoRI, and hybridized with digoxigenin-labeled mtDNA. As a control, we isolated the rho À mutant in the W303-MLC30 background by repeated plating of the cells on YPD plates containing 50 mg/ml of ethidium bromide.
11) The mtDNA of the control rho À strain lacked EcoRI fragments larger than 4 kbp, showing that a large portion of mtDNA was deleted (Fig. 2B) . In contrast, the mtDNA of the FMA treated cells showed a band pattern similar to that of DMSO-treated cells at all time points tested. In addition, the intensity of the mtDNA bands referred to total DNA showed little change in all samples tested. These results indicate that FMA causes neither replication block nor enhancement of degradation on mtDNA within 8 h of treatment.
Next we examined the sensitivity of rho À cells to FMA. The IC50 of the drug to rho À cells was 0.25 mg/ ml (0.46 mM), showing that the rho À cells are about 20 times more resistant to FMA than the rho þ cells (Fig. 1B) . In addition, the accumulation of G1 cells was not obvious after 8 h of incubation in the presence of 2 mg/ml of FMA. 
FMA changes mitochondrial morphology
In the cells treated with FMA, a few bright PIstainable spots, distinctive of nuclei by size, frequently appeared (Fig. 1E) , suggesting that FMA causes an aggregation of mtDNA and possibly introduces some change in mitochondrial morphology. To examine this possibility, we expressed Cox4p, the subunit IV of cytochrome c oxidase, with GFP fused in frame at the carboxyl terminus to visualize mitochondria. In the W303-MLC30 cells, mitochondria appeared as tubular networks distributed near the cell cortex (Fig. 3A) . After 4 h of incubation with 0.025% DMSO, no significant change in this mitochondrial morphology was detectable. In contrast, less than 3% of FMA-treated cells contained a normal mitochondrial network. Instead, FMA-treated cells contained between one and five amorphous or spherical mitochondrial structures. Under our microscopic conditions, the exact shape of the aberrant mitochondria that appeared in the presence of FMA could not be revealed, but, the vast majority of them are not spherical, suggesting that mitochondria cluster together, but do not fuse to each other. Next we examined the kinetics of this morphological change. Samples were withdrawn from the culture at various times and the percentage of the cells with aberrant mitochondria was counted under a fluorescent microscope. In the presence of FMA, about 75% of the cells contained aberrant mitochondria by 10 min, and the percentage gradually increased toward 60 min, to reach 95% (Fig. 3B) . A rapid increase in aberrant mitochondria was evident by the addition of FMA at concentrations over 0.1 mg/ml, but was not below 0.01 mg/ml. There is evidence that the actin cytoskeleton controls mitochondrial morphology and function, 12) and loss of F-actin by treatment with Latrunculin-A results in fragmentation of tubular mitochondria into short tubular and small spherical structures.
13) But, we detected no alteration in the structure or distribution of actin cables and patches during 8-h treatment with FMA (data not shown). We also tested the effect of FMA on W303-1A, and found that the drug caused accumulation of G1 cells, mitochondrial aggregation, and induced petite at a concentration of 5 mg/ml with similar kinetics to that observed in W303-MLC30 with 0.5 mg/ml of FMA (data not shown). These results indicate that the deletion of multi-drug resistance genes is not responsible for defects caused by FMA.
Overexpression of TOP1 does not alleviate the cytotoxicity of FMA
FMA is reported to totally inhibit topoisomerases I and II of mammalian cells at concentrations of 4.4 and 7.4 mM, respectively, and also to inhibit calf thymus DNA polymerase at an IC50 of 93 mM.
3) If this inhibition works in yeast cells, overexpression of either enzyme is expected to alleviate the defects caused by FMA. However, the W303-MLC30 cells carrying TOP1, a gene encoding topoisomerase I, on a high-copy vector (YEpTOP1) showed almost the same dose responsibility to FMA as W303-MLC30 cells carrying vector alone (Fig. 4) . In addition, FMA induced mitochondrial aggregation in W303-MLC30/YEpTOP1 with kinetics similar to that of the control vector transformants (data Drug conc., µg/ml Relative growth (%) Fig. 4 . Effect of the TOP1 Overexpression on the Sensitivity of the Cells to FMA. The W303-MLC30 rho þ cells carrying YEpTOP1 (pTOP1) or its vector were treated as described in Fig. 2A . Values are the averages of three independent experiments. not shown). Because the overexpression of topoisomerase II (TOP2) caused growth defect in our strain background, we could not assess the effect of TOP2 overexpression on the cytotoxicity of FMA. Taken together, inhibition of topoisomerase I might not be a major cause of cytotoxicity by FMA in yeast. Because topoisomerases functioning within mitochondria are not yet identified, 14) the possibility remains that FMA inhibit these enzymes to cause mitochondrial defects.
Hilton et al. have suggested that FMA mitht spontaneously reduce oxygen to create superoxyde with the generation of 1-electron oxidization of the quininoid half of the drug.
2) Superoxide is toxic, especially through inactivation of proteins that are contained in mitochondria, such as aconitase and succinate dehydrogenase. 15) To test whether FMA induces the production of reactive oxygen species (ROS), we co-incubated the cells with FMA and 5 mg/ml of diydrorhodamine 123, and fluorescence was monitored. 16 ) Diydrorhodamine 123 accumulates in the cells and is oxidized to fluorescent chromophore rhodamine 123 by ROS. 17) About 2% of the cells showed a rhodamine 123 fluorescence at the time 0 of incubation ( Table 1 ). The addition of FMA increased the number of cells with fluorescence to about 15% after 8 h of incubation, but did not increase in 30-min incubation (data not shown). The kinetics of the appearance of rhodamine 123 fluorescence was far slower than that of the cells with aberrant mitochondria (Fig. 3B) . Therefore, the increase in rhodamine 123 fluorescence in FMA-treated cells was thought to be a result, but not a cause, of the mitochondrial defect.
As described above, our results strongly indicate that the primary target site of FMA in yeast is mitochondria. At present, the mechanism by which the drug causes an accumulation of G1 cells is unclear. Singh et al. proposed the presence of a mitochondrial damage checkpoint that can adjust the cell-cycle response and gene expression to help repair damaged mitochondria to restore normal mitochondrial function. 18) In addition, a low dose of respiratory inhibitors induces cell-cycle arrest in G1 in human cells. 19) FMA might activate this checkpoint pathway to induce cell-cycle arrest.
FMA caused an aggregation of mitochondria. Mitochondria undergo frequent fission and fusion events that regulate their morphology, numbers and function. 20) Mitochondrial fission is required in dividing cells to ensure inheritance of organelles by daughter cells and mitochondrial fusion serves to maintain a tubular mitochondrial network and optimal mitochondrial function. Consequently, a balance between mitochondrial fission and fusion events is required for normal mitochondrial morphology and inheritance. Recent studies show that mutations in proteins involved in the fusion and fission of the organelle are associated with human diseases.
21) The target(s) of FMA might be the one which is involved in the mitochondrial fission and fusion events and/or its regulation. Although the composition of mitochondrial components in our rho À strain is obscure, the higher resistance of this strain to FMA suggest that the target of the drug might be contained in the components lost from mitochondria of this strain. Identification of FMA target(s) is expected to shed light on the mechanisms of mitochondrial dynamics. The W303-MLC30 rho þ cells were co-incubated with 0.5 mg/ml FMA (or 0.025% DMSO, FMAÀ) and 5 mg/ml of diydrorhodamine 123 for the indicated times, and cells with fluorescence were counted under a microscope (n ¼ 300). Values are the averages of three independent experiments.
